Form 4: Delaet Ingrid reports multiple insider transactions in NBIX
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Delaet Ingrid reported multiple insider transaction types in a Form 4 filing for NBIX. The filing lists transactions totaling 78,494 shares at a weighted average price of $124.05 per share. Following the reported transactions, holdings were 2,802 shares.
Positive
- None.
Negative
- None.
Insights
Routine NBIX insider equity vesting and grants; no open-market sales.
Ingrid Delaet, Chief Regulatory Officer of Neurocrine Biosciences, reported RSU and PRSU vesting into common stock, including 19,935 performance-based shares after metrics were certified at 125% of target. These events reflect standard long-term incentive structures rather than discretionary trading.
The filing also shows a stock option grant for 31,234 shares at an exercise price of $124.12 and a separate 5,479-RSU grant, each with multi-year vesting. Footnotes clarify that shares marked with code F were withheld to satisfy tax obligations, with no open-market sales.
Overall, this appears to be routine equity compensation activity for a senior officer, with the actual impact depending on long-term stock performance and future vesting. There is no indication here of unusual buying or selling behavior beyond tax withholding mechanics.
Insider Trade Summary
4,360 shares exercised/converted
Mixed
13 txns
Insider
Delaet Ingrid
Role
Chief Regulatory Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 1,401 | $0.00 | -- |
| Exercise | Restricted Stock Unit | 1,359 | $0.00 | -- |
| Grant/Award | Stock Option | 31,234 | $0.00 | -- |
| Grant/Award | Restricted Stock Unit | 5,479 | $0.00 | -- |
| Exercise | Common Stock | 1,401 | $0.00 | -- |
| Tax Withholding | Common Stock | 756 | $124.12 | $94K |
| Exercise | Common Stock | 1,359 | $0.00 | -- |
| Tax Withholding | Common Stock | 734 | $124.12 | $91K |
| Grant/Award | Common Stock | 19,935 | $0.00 | -- |
| Tax Withholding | Common Stock | 10,755 | $124.12 | $1.33M |
| Exercise | Restricted Stock Unit | 1,600 | $0.00 | -- |
| Exercise | Common Stock | 1,600 | $0.00 | -- |
| Tax Withholding | Common Stock | 881 | $123.10 | $108K |
Holdings After Transaction:
Restricted Stock Unit — 2,802 shares (Direct);
Stock Option — 31,234 shares (Direct);
Common Stock — 7,176 shares (Direct)
Footnotes (1)
- Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs") or performance restricted stock units ("PRSUs"), as applicable. No shares were sold. On May 19, 2023, the Reporting Person was granted PRSUs representing the right to receive shares of the Issuer's common stock based upon the achievement of specified performance metrics over the three-year performance period ending on December 31, 2025. Effective February 13, 2026, the achievement of the applicable performance metrics and the resulting payout level were certified, and, as a result of such certification, the PRSUs vested at 125% of the target number of shares subject to the award. Each RSU represents a contingent right to receive one share of the Issuer's common stock. This RSU was granted to the Reporting Person on February 12, 2025. In accordance with the terms of the RSU, the award vested as to 1,600 shares on February 12, 2026, and will vest as to 1,600 shares on February 12, 2027, 1,600 shares on February 12, 2028, and 1,601 shares on February 12, 2029, subject to the terms and conditions of the award. This RSU was granted to the Reporting Person on February 13, 2024. In accordance with the terms of the RSU, the award vested as to 1,401 shares on February 13, 2025, vested as to 1,401 shares on February 13, 2026, and will vest as to 1,401 shares on February 13, 2027, and 1,401 shares on February 13, 2028, subject to the terms and conditions of the award. This RSU was granted to the Reporting Person on February 13, 2023. In accordance with the terms of the RSU, the award vested as to 1,358 shares on February 13, 2024, vested as to 1,358 shares on February 13, 2025, vested as to 1,359 shares on February 13, 2026, and will vest as to 1,359 shares on February 13, 2027, subject to the terms and conditions of the award. Represents option of which 1/48th of the shares underlying the option becomes vested and exercisable on March 13, 2026 and an additional 1/48th of the shares underlying the option becomes vested and exercisable each month thereafter. The Restricted Stock Units will vest annually at 1/4 of the units vesting on each of February 13, 2027, February 13, 2028, February 13, 2029, and February 13, 2030.
FAQ
What did NBIX Chief Regulatory Officer Ingrid Delaet report on this Form 4?
Ingrid Delaet reported routine equity compensation activity, including RSU and performance RSU vesting into common stock and new equity awards. Events covered February 12–13, 2026 and reflect scheduled long-term incentive vesting and grants, rather than discretionary open-market share purchases or sales.
What performance-based award did NBIX report for Ingrid Delaet in this Form 4?
The filing shows performance RSUs granted in May 2023 that vested into 19,935 common shares after a three-year performance period. On February 13, 2026, achievement of the applicable performance metrics was certified, and the award paid out at 125% of the original target share level.
What new stock option grant did Ingrid Delaet receive from NBIX?
Delaet received a stock option covering 31,234 NBIX shares at an exercise price of $124.12 per share, expiring February 13, 2036. The option vests in 48 equal monthly installments, beginning March 13, 2026, aligning with a typical four-year vesting schedule for senior executives.
What new restricted stock units (RSUs) were granted to Ingrid Delaet by NBIX?
The Form 4 reports a grant of 5,479 restricted stock units to Delaet on February 13, 2026. These RSUs will vest in four equal annual installments, with one-quarter vesting on each of February 13, 2027, 2028, 2029, and 2030, subject to the award’s terms and conditions.
How were tax obligations handled for Ingrid Delaet’s NBIX RSU vesting?
For multiple vesting events, NBIX withheld common shares, reported under transaction code F, at prices around $123.10–$124.12 per share. Footnote language specifies these withholdings were solely to satisfy tax requirements and clarifies that no shares were actually sold in the market.